Assisted Reproductive Technology Market To Reach USD 179.4 Billion By 2033

Introduction

Global Assisted Reproductive Technology Market size is expected to be worth around USD 179.4 Billion by 2033, from USD 31.9 Billion in 2023, growing at a CAGR of 19.4 % during the forecast period from 2024 to 2033. In 2023, Europe led the market, achieving over 39.2% share with a revenue of US$ 12.5 Billion.

The market’s growth is primarily driven by key factors such as the increasing prevalence of infertility, advancements in technologies like cryopreservation and preimplantation genetic diagnosis, and growing government support to enhance access to fertility treatments.

However, the market faces challenges, including the high costs of treatment, ethical concerns around procedures like egg and sperm donation, and the physical and emotional toll on patients undergoing these treatments. Despite these obstacles, the market continues to grow, bolstered by ongoing research and development that has improved success rates and made treatments more accessible.

Recent developments in the ART market reflect significant investments and innovations. In 2022, FUJIFILM Irvine Scientific launched a new product, Heavy Oil for Embryo Culture, aimed at enhancing the efficiency and safety of IVF procedures. Additionally, CooperSurgical’s acquisition of Embryo Options and Hamilton Throne’s purchase of IVFTECH ApS highlight the industry’s focus on expanding technological capabilities and improving patient outcomes through strategic partnerships.

Overall, the ART market is positioned for remarkable growth, driven by advancements in medical technology, increased awareness of infertility treatments, and supportive government initiatives promoting accessibility and affordability.

Key Takeaways

• The global assisted reproductive technology (ART) market is expanding at a CAGR of 19.4% from 2023 to 2032.
• Accessory and disposable-type ART dominated the market in 2022, holding the largest share at 52.3%.
• In-vitro fertilization (IVF) was the most lucrative technology segment in 2022, with an 87% market share.
• Fresh non-donor procedures were the most profitable in 2022, representing 40% of the market.
• Fertility clinics were the leading end-users, contributing 40.5% to the ART market in 2022.
• Technological advancements, such as IVF and ICSI, have significantly improved ART success rates.
• Rising disposable incomes have made ART more accessible to a broader population.
• Increased awareness and government support are driving higher demand for ART services.
• Europe was the most lucrative ART market in 2022, with a 39.2% market share.
• The Asia Pacific region is experiencing rapid growth in ART due to rising awareness and demand.

Assisted Reproductive Technology (ART) Statistics

• IVF Births: In 2022, 91,771 babies were born via IVF, accounting for 2.5% of U.S. births, reflecting a 2.5% increase from 2021.
• ART Cycle Demand: ART cycles rose 6% to 389,993, indicating growing demand despite legislative challenges.
• Egg Freezing Trends: Egg-freezing cycles increased from 24,560 in 2021 to 29,803 in 2022, highlighting evolving patient preferences.
• Single Embryo Transfers (eSET): Usage of eSET rose, reducing multiple births from 5% to 4%.
• Safer Pregnancies: In 2022, 73.9% of cycles used single embryo transfer, supporting healthier pregnancies.
• Singleton Births: Nearly 96% of ART babies in 2022 were singletons, up from 80% in 2015.
• Live Birth Rates by Age: Success rates per intended egg retrieval: under 35: 43.1%, 35–37: 31%, 38–40: 19%, over 42: 3.2%.
• 2021 ART Cycles: In 2021, 238,126 patients underwent 413,776 ART cycles across 453 clinics in the U.S., resulting in 91,906 live births and 97,128 infants.
• Egg/Embryo Banking: 167,689 ART cycles involved egg or embryo banking for future use.
• Historical Data: In 2006, over 140,000 ART procedures were performed in the U.S., leading to 55,000 births.
• Initial Costs: Fertility workup costs range from $1,600 to $3,100, including procedures like hysteroscopy and sonohysterogram.
• IVF Costs: A single IVF cycle costs $15,600 to $46,800 in the U.S.
• Insurance Impact: States with mandated coverage see 278% higher fertility treatment usage.
• European ART Statistics: In 2015, 157,500 children were born using ART in Europe, with legislation varying by country.
• Global Access: Spain allowed ART for all women in 1977, while France granted the same in 2019.
• Israel’s Coverage: Israel’s national insurance covers nearly all fertility treatments, including IVF, for up to two children.
• Canada’s Policies: Some Canadian provinces partially fund fertility treatments, but most costs are out-of-pocket.
• India’s Regulation: India regulates ART through Surrogacy and ART Acts, allowing single women access to treatments.
• First IVF Birth: Louise Brown, the first IVF baby, was born on July 25, 1978, in England.
• ICSI Milestone: The first birth via Intracytoplasmic Sperm Injection (ICSI) occurred on January 14, 1992.
• Fertility Challenges: Globally, 8–12% of couples face infertility, with male factors contributing to 40–50% of cases.
• US Fertility Issues: About 10% of women aged 15–44 in the U.S. experience difficulty conceiving or maintaining pregnancy.
• ART-Conceived Infants: Approximately 1.9% of U.S. infants are conceived using ART.
• Dominant ART Procedure: IVF with Embryo Transfer (IVF-ET) constitutes 99% of ART procedures, showcasing its prevalence.
• IVF Success Rates by Age: IVF success rates decline with age: under 35: 52%, 35–37: 38.1%, 38–40: 23.5%, over 40: 7.6%.
• FET Success: In 2017, 52% of patients undergoing Frozen Embryo Transfer (FET) had ongoing pregnancies.
• ICSI Fertilization Rates: ICSI achieves fertilization rates of 50–80%, playing a key role in ART.
• Donated Embryos: Around 50% of transfers with donated frozen embryos result in pregnancy, with 40% leading to live births.
• Cost of IVF: Average costs for one IVF cycle range from $12,000 to $17,000, with FET procedures costing up to $6,000.
• Donation Costs: Sperm donation costs around $1,000 per vial, while egg donation expenses range from $18,000 to $50,000.
• Embryo Adoption: Costs for embryo adoption are between $13,000 and $17,000.
• Surrogacy Costs: Surrogacy expenses range from $60,000 to $150,000, reflecting significant financial investments.
• Ethical Issues: Challenges include gamete ownership, age limits, religious beliefs, and disclosure of genetic parentage.
• Deceased Gametes: Using gametes from deceased individuals raises complex ethical concerns.
• ART in 2021: In 2021, 86,146 ART infants accounted for 2.3% of U.S. births.
• Single Embryo Transfers by Age: Transfer rates for single embryos: under 35: 85.8%, 35–37: 85.1%, 38–40: 80.3%, over 40: 76.8%.
• Multiple Births: 12.5% of ART infants were multiples, including twins and triplets.
• Low Birth Weight: 14.7% of ART infants had low birth weights, compared to 8.5% in the general population.
• Preterm Births: 19.7% of ART infants were born preterm, compared to 10.5% of overall births.

Assisted Reproductive Technology (ART) in Japan (2021)

• ART Facilities and Treatment Cycles
  • Japan had 625 ART facilities, conducting 498,140 registered treatment cycles, a 10.7% increase compared to 2020.
• Neonates Born from ART
  • A total of 69,797 neonates were born through ART, reflecting a 15.5% rise from the previous year.
• Freeze-All IVF Cycles
  • Freeze-all IVF cycles reached 42,016, playing a significant role in ART treatments.
• IVF-Embryo Transfer (ET) Cycles
  • IVF-ET cycles resulted in 2,268 neonates, showcasing the effectiveness of this specific ART method.
• Intracytoplasmic Sperm Injection (ICSI)
  • ICSI cycles totaled 170,350, leading to the birth of 2,850 neonates.
• Frozen-Thawed Embryo Transfer (FET) Cycles
  • FET cycles rose by 11.2%, reaching 239,428 in 2021.
  • These cycles resulted in 87,174 pregnancies and 64,679 neonates, demonstrating their high success rate.
• Singleton Pregnancy and Live Birth Rates
  • Fresh transfers: Singleton pregnancy rate was 97.0%, and the live birth rate was 97.3%.
  • FET cycles: Singleton pregnancy rate was 96.9%, and the live birth rate was 97.1%.
• Demographic Profile of ART Patients
  • The mean patient age was 37.8 years.
  • Women aged 40 or older accounted for 39.9% of ART cycles, highlighting the increasing participation of older patients.
• Pregnancy and Success Rates
  • IVF pregnancy rate per embryo transfer: 23.6%.
  • ICSI pregnancy rate per embryo transfer: 18.8%.
  • FET pregnancy rate per embryo transfer: 36.9%, indicating higher success compared to fresh transfers.
• Miscarriage and Live Birth Rates for FET
  • Miscarriage rate per pregnancy: 24.8%.
  • Live birth rate per FET cycle: 26.6%.
• Impact of Maternal Age
  • Trends show declining pregnancy rates as maternal age increases, particularly beyond 40 years, underscoring the age-related challenges in ART success.

Emerging Trends

• Cryopreservation Advancements: Cryopreservation techniques have evolved significantly, with vitrification emerging as a breakthrough. Unlike slow freezing, vitrification rapidly cools biological material into a glass-like state, preventing ice crystal formation and enhancing cell viability. This advancement has substantially improved pregnancy success rates from frozen eggs and embryos, making vitrification the preferred method for preserving reproductive cells in ART procedures.
• In-Vitro Fertilization (IVF) Enhancements: IVF technologies have continually advanced, incorporating methods such as intracytoplasmic sperm injection (ICSI), assisted hatching, and preimplantation genetic testing (PGT). ICSI involves injecting a single sperm directly into an egg, boosting fertilization rates. Assisted hatching facilitates embryo implantation into the uterine wall, while PGT screens embryos for genetic abnormalities, ensuring healthier outcomes. These innovations collectively enhance IVF success rates and treatment efficacy.
• INVOcell Technology: INVOcell offers a cost-effective alternative to traditional IVF by enabling embryos to develop within a woman’s body rather than in a laboratory incubator. This approach reduces costs and provides a natural environment for embryo development. By leveraging the body’s natural conditions, INVOcell improves embryo development and implantation success. The process involves placing eggs and sperm in a small device, which is then inserted into the body for fertilization and early development.
• Endometrial Receptivity Array (ERA): The ERA test is a cutting-edge method to determine the optimal timing for embryo implantation. By analyzing gene expression in endometrial tissue, the test identifies the most receptive window for implantation. A small sample of endometrial tissue is analyzed to ensure embryo transfer occurs at the right time, significantly improving the chances of successful implantation and pregnancy. This personalized approach enhances ART outcomes.
• Artificial Intelligence (AI) Integration: AI is increasingly being used in fertility clinics to improve ART procedures. It assists in embryo selection by analyzing large datasets to predict which embryos have the highest potential for successful pregnancies. AI also optimizes treatment plans and predicts success rates, making ART procedures more effective and efficient. By providing data-driven insights, AI is transforming fertility treatments and improving patient outcomes.

Use Cases

• Infertility Treatment: ART, including IVF and ICSI, is vital for treating infertility, which affects 10–15% of couples globally, according to the World Health Organization. By fertilizing eggs and sperm outside the body and implanting embryos into the uterus, ART offers a viable solution for those unable to conceive naturally. It has become a cornerstone in addressing infertility challenges.
• Cancer Patients: For cancer patients, cryopreservation of eggs, sperm, and embryos before treatment is an essential fertility preservation option. Cancer therapies like chemotherapy and radiation can impair fertility. By freezing and storing gametes, patients ensure the possibility of having biological children in the future, enabling them to focus on recovery without the added concern of infertility.
• Single Mothers and Same-Sex Couples: ART provides a pathway to parenthood for single women and same-sex couples. Single women can use donor sperm, while same-sex couples may opt for donor gametes or surrogacy. With increasing social acceptance, ART usage in these groups is growing, offering them the opportunity to raise children who share their genetic heritage. This reflects a shift toward more inclusive family structures.
• Genetic Screening: Preimplantation Genetic Testing (PGT) screens embryos for genetic disorders before implantation. This process helps identify genetic abnormalities, ensuring only healthy embryos are transferred. PGT is especially beneficial for individuals with a history of genetic conditions or recurrent pregnancy losses, reducing the risk of inherited diseases and supporting healthier pregnancies and families.

Conclusion

The Assisted Reproductive Technology (ART) market is experiencing robust growth, driven by advancements in medical technologies, increased awareness of infertility treatments, and supportive government initiatives. Key innovations like vitrification, INVOcell, and AI integration are enhancing success rates and accessibility. Despite challenges such as high costs and ethical concerns, rising demand for ART services is evident across diverse demographics, including cancer patients, single mothers, and same-sex couples.

The market’s expansion is further supported by strategic investments and collaborations, particularly in Europe and Asia Pacific. ART continues to transform fertility care, offering viable solutions for individuals facing infertility and complex reproductive challenges.

Discuss your needs with our analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF